Patents Examined by Samira Jean-Louis
  • Patent number: 10105351
    Abstract: Disclosed herein are methods of treating a patient at risk of developing or having a neurofibromatosis or a sporadic schwannoma. In exemplary embodiments, the method involves administering to a subject in need an effective amount of a modulator of a target related to neurofibromatosis. Also disclosed are screening assays involving the implementation of Merlin-null Schwann cells, and to compounds identified using same.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: October 23, 2018
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventor: Cristina Fernandez-Valle
  • Patent number: 10077246
    Abstract: Prodrugs (I) and (Ia) of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: September 18, 2018
    Assignee: Glactone Pharma Development AB
    Inventors: Martin Johansson, Olov Sterner
  • Patent number: 10071104
    Abstract: An implant comprising testosterone or an ester thereof and an aromatase inhibitor; the aromatase inhibitor may be selected from the group consisting of anastrozole, letrozole, and exemestane. In one embodiment the implant is a sustained release, subcutaneous implant. Also disclosed are therapies for patients with symptoms of relative androgen deficiency, breast cancer survivors and other therapies in which testosterone is indicated but elevated estradiol levels are avoided.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: September 11, 2018
    Inventor: Rebecca L. Glaser
  • Patent number: 10071109
    Abstract: CYP2W1 levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of a hypoxia-activated achiral phosphoramidate mustards.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: September 11, 2018
    Assignee: Molecular Templates, Inc.
    Inventors: Brian A. Elenbaas, Lei Shen
  • Patent number: 10064851
    Abstract: Provided is a method of increasing the stability of wild-type ?-glucocerebrosidase. Also provided are methods of treating and/or preventing an individual having a neurological disease in which increased expression or activity of ?-glucocerebrosidase in the central nervous system would be beneficial. This method comprises administering an effective amount of a pharmacologic chaperone for ?-glucocerebrosidase, with the proviso that the individual does not have a mutation in the gene encoding ?-glucocerebrosidase. Further provided are ?-glucocerebrosidase inhibitors which have been identified as specific pharmacologic chaperones and which have been shown to increase activity of ?-glucocerebrosidase in vivo in the central nervous system.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: September 4, 2018
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Brandon Alan Wustman
  • Patent number: 10051880
    Abstract: A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: August 21, 2018
    Assignees: OXFORD UNIVERSITY INNOVATION LIMITED, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Kieran Clarke, Richard Lewis Veech
  • Patent number: 10052386
    Abstract: Various pharmaceutical formulations are disclosed herein. For example, a pharmaceutical formulation is disclosed comprising ultra-micronized progesterone.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: August 21, 2018
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Julia M. Amadio, Peter H. R. Persicaner, Janice Louise Cacace, Thorsteinn Thorsteinsson, Frederick D. Sancilio
  • Patent number: 10047051
    Abstract: The invention discloses compounds of Formula I wherein X, R1, R2, and R3 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: August 14, 2018
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Marlon D. Cowart, Tom Roger Lisette De Munck, Sébastien Jean Jacques Cédric Dropsit Montovert, Gregory A. Gfesser, Hans Kelgtermans, Sébastien Laurent Xavier Martina, Steven Emiel Van der Plas, Xueqing Wang
  • Patent number: 10035811
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: July 31, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • Patent number: 10022380
    Abstract: A cell permeable iron chelator, optionally in combination with an autophagy inhibiting agent, is used for treating a solid cancer tumor in a person. A preferred chelator is an alkyl substituted N-(1-pyridine-2-yl-methylidene)-N-(9H-1,3,4,9-tetraaza-fluoren-2-yl)-hydrazine. A preferred autophagy inhibiting agent is chloroquine. Also disclosed is a pharmaceutical composition comprising iron chelator, pharmaceutically acceptable carrier and, optionally, autophagy inhibiting agent; and a method of treating cancer by administering cancer combating-effective amount(s) of the iron chelator or the combination of iron chelator and autophagy inhibiting agent.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: July 17, 2018
    Assignee: VIVOLUX AB
    Inventors: Stig Linder, Mårten Fryknäs, Rolf Larsson
  • Patent number: 10022383
    Abstract: A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: July 17, 2018
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Nicholas E. Goeders, Christopher Dalton Schmoutz
  • Patent number: 10011592
    Abstract: Disclosed is a polycyclic inhibitor of anaplastic lymphoma kinase as represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof. Also disclosed is a method for preparing the compound, a pharmaceutical preparation and a pharmaceutical composition comprising the compound, and use of the compound, the pharmaceutically acceptable salt or stereoisomer thereof in manufacture of a medicament for the treatment and/or prevention of, for example, an anaplastic lymphoma kinase-mediated cancer or non-cancer related diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: July 3, 2018
    Assignee: XUANZHU PHARMA CO., LTD.
    Inventor: Frank Wu
  • Patent number: 10010536
    Abstract: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: July 3, 2018
    Assignee: INTERMUNE, INC.
    Inventors: Lawrence M. Blatt, Scott D. Seiwert, Leonid D. Beigelman, Ramachandran Radhakrishnan, Karl Kossen, Vladimir Serebryany
  • Patent number: 9993451
    Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: June 12, 2018
    Assignee: NeuroDerm, LTD.
    Inventors: Oron Yacoby-Zeevi, Mara Nemas
  • Patent number: 9987271
    Abstract: A method of treating nasopharyngeal carcinoma in a mammal includes delivering to the mammal a therapeutically effective amount of a perillyl alcohol (POH) carbamate which is a perillyl alcohol conjugated with temozolomide (TMZ).
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: June 5, 2018
    Assignee: NeOnc Technologies, Inc.
    Inventor: Thomas Chen
  • Patent number: 9987266
    Abstract: Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: June 5, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman, Chunjian Liu
  • Patent number: 9980967
    Abstract: EGFR mutation (T790M) and cancerous stemness have shown drug resistances in human non-small-cell lung cancer (NSCLC), thus development of novel drugs in overcoming drug resistances in the NSCLC therapy is highly desired. SP101 is a novel gefitinib derivative, which can bind the ATP-binding pocket of EGFR to inhibit its EGFR kinase activity. SP101 can reduce the drug resistances of EGFR mutation (T790M) and cancerous stemness in NSCLC. SP101 induced cancer cell death and apoptosis in the gefitinib-resistant EGFR mutation (T790M) H1975 cells. SP101 inhibited phosphorylated EGFR and its downstream Survivin proteins but conversely induced Caspase 3 activation for apoptosis induction. Moreover, SP101 could decrease Oct4 protein level and reduce Survivin proteins but conversely elicited active Caspase 3 in the xenograft human H1975 lung tumors in nude mice.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: May 29, 2018
    Assignee: National Chiao Tung University
    Inventors: Jui-I Chao, Kuang-Kai Liu, Ya-Ping Hsu
  • Patent number: 9980941
    Abstract: A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: May 29, 2018
    Inventor: Steven A. Rich
  • Patent number: 9969683
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject. The breast cancer includes metastatic breast cancer, refractory breast cancer, AR-positive breast cancer, AR-positive refractory breast cancer, AR-positive metastatic breast cancer, AR-positive and ER-positive breast cancer, triple negative breast cancer, advanced breast cancer, breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments, and metastasis in a subject suffering from breast cancer. The method comprises administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: May 15, 2018
    Assignee: GTX, INC.
    Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
  • Patent number: 9969698
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: May 15, 2018
    Assignee: REXAHN PHARMACEUTICALS, INC.
    Inventors: Deog Joong Kim, Young Bok Lee, Reza Mazhari, Daniel Edward Emrich